Skip Navigation


JAC Advance Access originally published online on February 10, 2005
Journal of Antimicrobial Chemotherapy 2005 55(3):317-319; doi:10.1093/jac/dki022
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/3/317    most recent
dki022v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Carrillo-Muñoz, A.-J.
Right arrow Articles by Santos, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carrillo-Muñoz, A.-J.
Right arrow Articles by Santos, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC vol.55 no.3 © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved

Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections

Alfonso-Javier Carrillo-Muñoz1,*, Guillermo Quindós2, Maite Ruesga2, Rocío Alonso2, Oscar del Valle3, Juan Manuel Hernández-Molina4, Paul McNicholas5, David Loebenberg5 and Patricia Santos6

1 Departamento de Microbiología, ACIA, PO Box 10178, E-08080 Barcelona; 2 Departamento de Inmunología, Microbiología y Parasitología, Facultad de Medicina, Universidad del País Vasco, Bilbao; 3 Servicio de Microbiología, Hospital Vall d'Hebrón, Barcelona; 4 Servicio de Microbiología, Hospital La Inmaculada, Huércal-Overa, Almería, Spain; 5 Schering-Plough Research Institute, Kenilworth, NJ, USA; 6 Hospital de Pediatría Pablo Garrahan, Buenos Aires, Argentina

* Corresponding author. Tel/Fax: +34-93-4297120; Email: acarrillo{at}ya.com

Objectives: The in vitro antifungal activity of posaconazole was compared with that of fluconazole and amphotericin B.

Materials and methods: A microdilution method (M27-A2) was used with 331 clinical yeast isolates.

Results: The geometric mean MICs of posaconazole, fluconazole and amphotericin B were 0.16, 0.91 and 0.15 mg/L, respectively. Posaconazole was markedly more active than fluconazole and was active against 9/11 fluconazole-resistant Candida albicans, and five Candida glabrata had an MIC of posaconazole of 16 mg/L.

Conclusions: These data indicate that posaconazole is a potentially effective antifungal agent for the treatment of mycoses caused by yeasts.

Keywords: susceptibility , opportunistic , Candida


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
M. I. Morris
Posaconazole: A new oral antifungal agent with an expanded spectrum of activity
Am. J. Health Syst. Pharm., February 1, 2009; 66(3): 225 - 236.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. L Berg, C. W Crank, A. H Philbrick, and M. K Hayden
Efficacy of Ertapenem for Consolidation Therapy of Extended-Spectrum {beta}-lactamase-Producing Gram-Negative Infections: A Case Series Report
Ann. Pharmacother., February 1, 2008; 42(2): 207 - 212.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.